UK parents' attitudes towards meningococcal group B (MenB) vaccination: a qualitative analysis by Jackson, C et al.
 1Jackson C, et al. BMJ Open 2017;7:e012851. doi:10.1136/bmjopen-2016-012851
ABSTRACT
Objectives (1) To explore existing knowledge of, 
and attitudes, to group B meningococcal disease and 
serogroup B meningococcal (MenB) vaccine among 
parents of young children. (2) To seek views on their 
information needs.
Design Cross-sectional qualitative study using individual 
and group interviews conducted in February and March 
2015, prior to the introduction of MenB vaccine (Bexsero) 
into the UK childhood immunisation schedule.
Setting Community centres, mother and toddler groups, 
parents’ homes and workplaces in London and Yorkshire.
Participants 60 parents of children under 2 years of age 
recruited via mother and baby groups and via an advert 
posted to a midwife-led Facebook group.
Results Although recognising the severity of meningitis 
and septicaemia, parents’ knowledge of group B 
meningococcal disease and MenB vaccine was poor. While 
nervous about fever, most said they would take their child 
for MenB vaccination despite its link to fever. Most parents 
had liquid paracetamol at home. Many were willing to 
administer it after MenB vaccination as a preventive 
measure, although some had concerns. There were mixed 
views on the acceptability of four vaccinations at the 
12-month booster visit; some preferred one visit, while 
others favoured spreading the vaccines over two visits. 
Parents were clear on the information they required before 
attending the immunisation appointment.
Conclusions The successful implementation of the MenB 
vaccination programme depends on its acceptance by 
parents. In view of parents’ recognition of the severity of 
meningitis and septicaemia, and successful introduction 
of other vaccines to prevent bacterial meningitis and 
septicaemia, the MenB vaccination programme is likely 
to be successful. However, the need for additional 
injections, the likelihood of post-immunisation fever 
and its management are issues about which parents 
will need information and reassurance from healthcare 
professionals. Public Health England has developed written 
information for parents, informed by these findings.
INTRODUCTION
Following the successful introduction of 
meningococcal C (MenC) vaccine in 1999,1 
serogroup B is the leading cause of menin-
gococcal disease in the UK accounting for 
85%–90% of all cases and with the highest 
incidence in infants.2 In September 2015, 
the UK introduced routine meningococcal 
B vaccination (MenB) into the childhood 
immunisation schedule at 2, 4 and 12 months 
of age.3
The successful implementation of vaccines 
depends on many factors including parental 
acceptability. Since meningitis is recognised 
by parents to be a serious, potentially 
life-threatening infection4 and the perceived 
severity of an infection is an important deter-
minant of vaccine acceptance,5 the prospects 
for a successful MenB programme are good. 
However, the introduction of MenB vaccine 
raises specific issues, which may impact on 
its acceptability for some parents and which 
need addressing to ensure successful imple-
mentation.
First, although MenB is well evaluated in 
trials and in campaigns,6 7 the UK is the first 
country to introduce Bexsero (a specific MenB 
vaccine) as a publicly funded programme to 
help prevent group B meningococcal disease. 
Second, more injections are needed: a total 
of three at the 2-month and 4-month vacci-
nation visits and four at the 12-month visit. 
Endorsement by healthcare professionals 
plays an important role in parental accep-
tance of multiple injections8 9; however, an 
increasing number of vaccines and multiple 
injections offered routinely concerns some 
parents who feel, although misguidedly, that 
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Strengths and limitations of this study
 ► This is the only current UK study providing detailed, 
up-to-date information for Public Health England 
and primary care health professionals to facilitate 
the successful implementation of serogroup B 
meningococcal vaccine.
 ► A mix of parents across parental age, ethnicity and 
number of children were recruited; these parental 
characteristics are associated with uptake of 
childhood vaccination.
 ► Parents with a university degree or fully immunised 
children were over-represented in the study.
group.bmj.com on August 24, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Jackson C, et al. BMJ Open 2017;7:e012851. doi:10.1136/bmjopen-2016-012851
Open Access 
too many vaccines may overwhelm their child’s immune 
system.4 Parents also worry about increased pain and 
possible adverse events following multiple injections.9 
In the USA, where more vaccines and vaccine doses are 
recommended, some parents are reported to delay or 
even decline vaccines.10 In view of some existing parental 
concern about the number of vaccines already recom-
mended, there is the potential for this to be mirrored in 
the UK.
Third, when MenB vaccine is administered to infants 
concomitantly with other vaccines, it gives rise to higher 
levels (51%–61%) of fever (≥38°C) compared with 
routine vaccines given alone (23%).7 To reduce this risk, 
the Joint Committee on Vaccination and Immunisation 
recommended that when MenB vaccine is given with the 
other vaccines at 2 and 4 months of age, parents should be 
advised to administer paracetamol prophylactically.3 This 
represents a change in advice on managing fever, based 
on the National Institute for Health and Care Excellence 
guidance, that antipyretics should not be given in antici-
pation of a fever and only if a child appears distressed.11 
Since fever is also a concern for parents,12 13 they will be 
required to consider the balance of risks between the 
threat of meningitis and the likelihood of fever following 
the vaccine.
We aimed to explore parents’ knowledge of, and atti-
tudes to, MenB disease and MenB vaccine. We also 
sought views on their information needs, which included 
commenting on the content of communications devel-
oped by Public Health England (PHE). These comments 




This was a cross-sectional qualitative study.
Participants and recruitment
A large body of literature,14–19 identifies two broad catego-
ries of parental factors influencing uptake of childhood 
vaccination. The first relates to socioeconomic disadvan-
tage where, despite being motivated to have their children 
vaccinated, parents lack access to resources and support 
to overcome logistical barriers such as no private trans-
port (access). The second relates to parents’ concerns 
about the safety or beliefs about the necessity of vaccines 
(acceptance). To ensure that we spoke with parents in 
both categories, we set out to recruit 60 parents of chil-
dren under the age of 2 years across different parental 
age, socioeconomic status (using education as a proxy), 
ethnicity and number of children.
Parents were recruited in London and Yorkshire. In 
London, parents were recruited in five Children’s Centres 
(CC) from two London districts, which were selected for 
their sociodemographic mix. Written permission was 
secured to conduct the study in these CCs. HB attended 
mother and baby sessions in the CCs and distributed 
study information to parents, returning a week later to 
conduct interviews with consenting parents. In Yorkshire, 
parents were recruited from two mother and toddler 
groups (after securing permission from group leaders) by 
distributing study information and via an advert posted 
to a midwife-led Facebook group. Interested mothers 
contacted CJ for more information and interviews were 
conducted subsequently. We did not formally record 
how many parents were approached and then agreed/
declined to be interviewed.
Data collection
Individual and group interviews were conducted by CJ and 
HB in February and March 2015 prior to the announce-
ment of the introduction of MenB vaccine. Both have 
considerable experience as immunisation researchers; 
and HB was previously a health visitor. They presented 
themselves to participants as independent to the MenB 
vaccination programme and advised that any specific 
questions about immunisation would be answered after 
the interviews. The written study information reassured 
parents that they could end/leave the interview at any 
point without offering a reason why. Parents who indi-
vidually contacted the research team to participate were 
interviewed on their own in their home or workplace. 
Parents recruited through the CCs and mother and 
toddler groups took part in group interviews conducted 
away from the main mother and baby session. The topic 
guide (see online supplementary file 1) was piloted with 
four parents of children under the age of 2 years. No 
changes were made. Interviews explored:
 ► Awareness of MenB disease and vaccine
 ► Perceptions of fever
 ► Attitudes to use of paracetamol as a prophylactic for 
fever
 ► Attitudes to an increased number of injections at 
each vaccination visit
 ► Preferences for the number of injections at each 
vaccination visit
 ► The most important information needed in the 
MenB leaflets
In the group interviews, the researcher asked partic-
ipants in turn to respond to the interview questions. 
Individual interviews lasted between 28 and 57 min. 
Group interviews lasted between 30 and 65 min. All inter-
views were digitally audio-recorded.
Data analysis
The audio-recordings were transcribed verbatim and 
personal data anonymised. The individual and group 
interview data were analysed together using the six 
steps of thematic analysis. This is a method of ‘identi-
fying, analysing and reporting patterns (themes) within 
the data’: p4. 20 It is a useful approach for producing 
qualitative analyses suited to informing programme 
development. The six steps were as follows:
 ► Familiarisation: both researchers (CJ and HB) 
became immersed in the raw data by ‘repeated 
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reading’ of the transcripts and listed key ideas for 
coding.
 ► Generating initial codes: initial codes and a coding 
framework were developed by CJ, informed 
predominantly by the study objectives (a deductive 
approach), although novel views expressed by 
participants were also captured (an inductive 
approach). The interview data were then coded by 
CJ to this framework using NVivo V.10 software.
 ► Searching for themes: the codes were then organised 
by CJ into potential themes and subthemes. At this 
point, similarities and differences in views across 
education, ethnicity and number of children were 
explored.
 ► Reviewing themes: the coded data within each 
potential theme were reviewed by CJ and HB and 
the themes modified to ensure that they formed a 
coherent pattern. Each theme was then reviewed to 
see if it ‘worked’ in relation to the entire data set.
 ► Defining and naming themes: a short paragraph was 
produced by CJ for each theme and subthemes to 
define the ‘essence’ of the theme/subthemes and 
names were allocated.
 ► Producing the report: the thematic analysis was 
written up by CJ.
Ethics approval
University College London Research Ethics Committee 
approved the study and parents gave written informed 
consent to take part.
FINDINGS
Participants
Information was gathered from 60 parents (table 1) 
through 7 individual and 12 group interviews (range 2–7 
parents). While the sample size was prespecified, data 
saturation occurred in that no new relevant knowledge 
emerged in the final few interviews. Two-thirds (62%) 
lived in London and one-third (38%) were from York-
shire. Participants were predominantly female (92%) and 
two-thirds (65%) were first time parents. Their age range 
was 20–43 years. Half were white British (55%). Half 
(55%) were educated to Bachelor degree or higher. Two 
parents were medically trained. Participants’ children 
(n=62) ranged from 12 days to 24 months of age. Almost 
all participants (92%) self-reported that their child/chil-
dren were fully immunised.
Parents’ views
We have reported findings based on thematic analysis of 
the data. Where views differ according to parents’ char-
acteristics, these are indicated. Illustrative quotes are 
presented throughout.
Views on MenB disease and vaccination
Knowledge about MenB and perception of risk of the disease
Although most parents were unfamiliar with the term 
‘meningococcal disease’, they had heard of meningitis, 
recognising it to be life threatening and needing urgent 
medical attention. They identified high temperature, 
fever and a rash (recognised using the glass test) as symp-
toms to look out for (quote 1, table 2). Parents were 
generally unsure of details of how meningococcal infec-
tion spreads, its incidence and who is most likely to catch 
it (quote 2, table 2). A minority of parents mentioned 
different strains (commonly C), but they were less aware 
of how strains differ, although it was suggested the differ-
ence was viral-bacterial or due to severity. Parents were 
generally less knowledgeable about septicaemia but knew 
it to be serious. Four parents who were well informed 
about both forms of meningococcal disease were either 
medically trained or had paid privately for their children 
to have the MenB vaccination.
Table 1 Parent characteristics
N %
Site London 37 62
Yorkshire 23 38
Gender Male 5 8
Female 55 92
Ethnicity White British 33 55




Black African 5 8
Asian Chinese 1 2
































Mean age of parent (years) 31.6 (5.10) 20–43
Mean age of children under 
2 years (months)
8.7 (5.60) 12 days to 
24 months
GCSE, General Certificate of Secondary Education.
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Knowledge of and attitudes to MenB vaccine
Some parents knew that there were vaccines in the 
schedule to protect against meningococcal disease, they 
most commonly mentioned MenC. Most had not heard 
of MenB vaccine. Because of this parents did not initially 
identify any safety concerns associated with MenB vaccine, 
although a small minority talked about feeling nervous 
when a new vaccine is introduced and their concerns that 
it has been sufficiently tested (quote 3, table 2). The four 
parents who were well informed about MenB disease were 
also knowledgeable about MenB vaccine, although a GP 
had not yet heard about it in her professional role (quote 
4, table 2).
Views on the increased risk of fever following vaccina-
tion
Managing fever
Most parents expressed worry about fever, particularly 
its cause and how it might progress, for example, febrile 
convulsions (quote 1, table 3). They described a variety of 
strategies to manage fever: removing clothing, applying 
a damp cloth/putting the child in the bath, checking 
the child’s temperature and administering liquid parac-
etamol (identified as Calpol). While many parents 
discussed using Calpol, a small number acknowledged 
that it cannot be used extensively with very young babies 
(quote 2, table 3). Some recognised that their confidence 
in managing fever had developed as their child got older 
as they ‘could gauge’ the child better (quote 3, table 3).
Concerns about fever
Most parents described becoming concerned about fever 
based on their child’s temperature and if it persists (quote 
4, table 3). At this point, they would seek advice from their 
GP or Health Visitor, telephone 111 or if very concerned 
go to Accident and Emergency. First-time mothers were 
more likely to report seeking help immediately, often 
from a knowledgeable family member.
Fever caused by vaccination
Some parents said that they would be less worried knowing 
a fever is caused by vaccination in that, to some extent, it 
is expected (quote 5, table 3) with a few commenting that 
fever is preferable to meningitis (quote 6, table 3).
Other parents expressed concern that a vaccine would 
elicit fever. Several of these, most of whom were first-time 
parents, talked about this being particularly worrying 
when their child is aged 2 months. This was because it is 
their first appointment for vaccinations, they do not know 
their baby well yet and cannot administer much Calpol to 
a child so young (quote 7, table 3).
Would the fever deter parents from accepting MenB vaccine?
The overwhelming majority of parents said that despite 
the link with fever, it would not prevent them having 
MenB vaccine. A few explained that this is because they 
trust that it has been tested and is safe (quote 8, table 3). A 
minority talked about making specific preparations such 
as considering the timing of the appointment (quote 9, 
table 3) or looking into this vaccination very carefully to 
be reassured it is worth having.
Acceptability of administering paracetamol post-vaccination
Routine administration of paracetamol
Most parents said that they have Calpol at home and 
routinely use it, although not when a child is aged only 
2 months (quote 1, table 4). A small minority of parents 
described having difficulties giving their child Calpol as 
he/she spits it out. Two parents appeared to not know that 
Calpol is liquid infant paracetamol. A few parents (one 
GP) pointed out that the regular instructions for adminis-
tering Calpol to a baby aged 2 months are different to the 
advice for use of paracetamol post-MenB vaccination; and 
that this inconsistency might worry and confuse parents 
(quote 2, table 4). Two parents did not agree with giving 
their child paracetamol because of concerns about its 
side effects and the view that it is used far more routinely 
Table 2 Illustrative quotes—knowledge of, and attitudes to, MenB disease and vaccination
1 Q. So what do you know about meningitis?
I know that it can cause fatality, it's very important to be identified quickly, and get the child medical help as, as soon as 
possible; and you usually associate it with the rash, like you know the clear glass you put on the, on the rash, it doesn't go 
away.
Y004a (White British father, fully immunised children, individual interview)
2 How it can come on, it can progress, that, I mean I wouldn’t know that, so, and I wouldn’t know the symptoms of it 
either…. or if they did have it, you know, I wouldn’t know what would be worrying or what; I mean, you know, kids get 
fevers and they get, you know, ear infections, chest infections, things like that, but I wouldn’t know what would mean it’s 
this, how would you know it’s definitely this?
Y008a (White British mother, fully immunised children, individual interview)
3 It's gonna need more information, I think, because it's a new vaccine, everyone's gonna be wary of it, it's not an old vaccine 
that's been around for years already, and I think for a new vaccine they're gonna need to put more information than that on 
it, personally, because obviously everyone's gonna be wary of it.
L007g (Asian British mother, non-immunised children, group interview)
4 Q: So you hadn’t heard of it in your role as a GP?
No. No, I hadn’t heard of it, and, and it does tend to be at the point of implementation that we, we tend to hear…cos 
there’s so much, so much going on I suppose all the time.
Y009a (White British mother, fully immunised children, individual interview)
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Table 3 Illustrative quotes—views on fever
1 Yeah, it's, it's scary. Two weeks ago she had a fever, she had it at about, almost 40 her fever was, and it, it is really scary, 
cos she would literally get really hot to where her face goes red, she's all sweating, then she'll cool down and get really, 
really hot again, and it's really hard to manage cos you don't know what to do, cos you don't know whether you should be 
putting cold, cold towel on them like, but you don't wanna shock their body into like all this cold, coldness at once, cos 
that's where they start, they start fitting. She had a, a small little fit, like a small convulsion, cos she got too hot.
L007g (Asian British mother, non-immunised children, group interview)
2 See that's, the only, the only problem that you have with that is that when they're eight weeks old, no, four weeks old, 
anything under the, under the age of three months you have to be careful how much Calpol and stuff you can give them, 
and the only thing you can give them is Calpol. So they are really careful, they, they do tell you to be really careful, but. So 
if they get a really bad fever, you can only give them one dose of Calpol in a 24 hours period, and that's the 2.5. I mean that 
should work, but if it didn't you're a bit stuck as a parent as to what you can do to help baby settle down.
Y006a (White British mother, fully immunised children, group interview)
3 I feel that now she’s nine months I’m, I’m more confident when she gets sick or has, has had a fever now, I understand her 
more and I have natural instincts of how to look after her and how bad she is I can gauge, where when she was younger 
and she did get a fever from some, the, I think it was the two months, the sixteen week one, I’m not sure, that I was so 
scared when she was, fell ill and, you know, the, the only kind of conversation you get is, if they should get a temperature 
give them Calpol, but you’re just so stressed as it is when they’re so young that to have it so, to have it so young is just, to 
gauge the fever that young is more scary than when they are older, yeah.
L008d (British Philippines mother, fully immunised children, group interview)
4 It (NHS Choices) tells you if a temperature lasts more than three, seventy two hours that you should be worried. I know from 
my personal experience when (name of daughter) had a temperature and I have, and it’s not been breaking for more than 
about forty-eight hours, that’s when I've started to worry.
L005a (White British mother, fully immunised children, individual interview)
5 And, and what I find reassuring with the imm, immunisation induced fevers you sort of know what it is, whereas if it's just a 
random, you know, incident, you'd never, I don't know, I'd be more worried if I, if it was non-immunisation related.
L001a (White British mother, fully immunised children, group interview)
6 It's better than meningitis.
Y007a (White British mother, fully immunised children, group interview)
I'd rather him have a fever…
Y007b (White British mother, fully immunised children, group interview)
That's what I mean, you can, you can control fever with Calpol and certain things. If they get baby ill from not having the 
vaccine, it's a lot harder to control than a fever.
Y007a
7 I, I wouldn't be happy with it. Cos at 2 months you’ve not given her paracetamol before and you don't know what the side 
effects are. If she had a fever I would give it to her. But no, I wouldn't like the idea of, personally, at so young.
L004a (White British mother, fully immunised children, group interview)
8 Q. Would you have it for your baby if the MenB vaccine was introduced?
I’d be so worried about a brand new vaccine, like our generation being kind of tested on it almost, but I think if it was the 
fact that everyone did and it’s, I probably would, I’d be worried about it though, but I would, if it was, yeah.
L003c (Black British African mother, fully immunised children, group interview)
Q. Because it’s a new thing?
Yeah, it’s a new thing and they’ve been tested, you know, but I think, I think I would.
L003c
Yeah, again I probably would, I mean it, I would probably, the increased risk of fever would be worrying, but I think if there’s 
anything that they can be protected against, I tend to just go along with what the government are recommending, and if 
they, if they say it’s safe and I tend to just believe that that’s, that’s true (laughs) trust that it’s true, and, and go with it, and 
I think I’d rather have them immunised against something and have a little bit of a fever for a day than not, and just them, 
them catching something awful. (laughs)
L003g (White British mother, fully immunised children, group interview)
I'd still have to be so convinced that it was worth it for, to have fever and for them to be having extra stuff in their bodies…
I'd need to be really convinced it was worthwhile.
L003a (Polish mother, partially immunised children, group interview)
9 Q. Does that (the fever) change how you feel about taking him?
It doesn’t, for me not necessarily, no, cos I suppose at least if you know it’s gonna happen you can be equipped with 
the tools to deal with it, and you can be practical in terms of when you go and have that done and being ready for it and 
working around it.
Y005a (White British mother, fully immunised children, individual interview)
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in the UK compared with their home country (quote 3, 
table 4).
Administration of paracetamol as a preventive measure
Views on parents’ willingness to administer prophylactic 
paracetamol after MenB vaccination differed. Many 
parents would be willing to administer paracetamol on 
the assumption that this is best for their child, even if 
they were worried about doing so (quote 4, table 4). 
However, questions were raised about whether they 
should wake a sleeping baby to administer a dose, or 
whether the third dose could be given the following 
morning, and what should they do if they forget to give 
the paracetamol or if the paracetamol does not work 
(quote 5, table 4).
However, a few parents expressed worries about admin-
istering prophylactic paracetamol. Reasons for this were 
a preference not to give paracetamol to their child gener-
ally, that their child struggles to take paracetamol (they 
spit it out), a worry about putting something else into 
the child’s body after vaccination and that paracetamol 
might mask vaccine side effects. Several of these parents 
explicitly stated that they would not give their child the 
paracetamol after MenB vaccination unless the child 
develops a fever (quote 6, table 4).
Acceptability of four injections at the 12-month booster visit
Most parents were accepting of the vaccination schedule, 
trusting that it is informed by sound research and there-
fore safe (quote 1, table 5). A small number mentioned 
that the schedule is complex and busy, which can be partic-
ularly hard to ‘keep a handle on’ with a new baby. Views 
on the acceptability of four injections at the 12-month 
appointment differed.
Some parents (often with more than one child) 
preferred all four injections in one visit. This view was 
based on practical reasons such as the inconvenience of 
booking and finding time to attend multiple appoint-
ments, particularly for those mothers who have returned 
to work by 12 months (quote 2, table 5). They acknowl-
edged that there would be an increased likelihood of them 
missing appointments if they are on different days. These 
parents also talked about preferring to ‘get it all over with 
in one go’ in terms of reducing distress to the child at the 
appointment and afterwards (quote 3, table 5). A few of 
these parents spoke about their child being more ‘robust’ 
by 12 months and so they felt more comfortable in taking 
them for multiple injections at that age.
Just over half of parents expressed a preference to sepa-
rate the vaccines over different visits with most preferring 
two injections at two visits a month apart, although two 
Table 4 Illustrative quotes—acceptability of administering paracetamol post-vaccination
1 Q. Has everybody got paracetamol at home?
About two months I didn't, but now he's getting a bit older I have got some in, in, just in case, cos of teething and 
vaccinations and everything else. But at, at, at two months probably not.
L007e (White British mother, fully immunised children, group interview)
2 People will worry about, cos it says, the, the advice on the bottle is from three months and then there’s just like a one-off 
post-immunisation dose in younger ones. So you’d have to be quite clear that it was safe; I think parents will worry about 
the safety of giving more than, more paracetamol than is prescribed on the bottle you’re buying.
Y009a (White British mother, fully immunised children, individual interview)
3 I have allergic just when you're saying paracetamol. I'm not agreeing with paracetamol. I know a whole country they been 
treating with paracetamol but I don't accept this.
Q: But in terms of fever and how to deal with it?
It, but you under, just look, they treat you with everything, all sickness they give you paracetamol, it's can't be, can't be 
helpful this stuff. But if you understand me, I don't, I'm not gonna use paracetamol.
L002a (Polish mother, fully immunised children, group interview)
4 I suppose if I knew it was gonna stop him being unwell I’d do it. So I suppose if they’re saying there’s a higher risk that he’s 
gonna be unwell straight after it, give him Calpol to try and make him comfortable I wouldn’t have a concern with that. But 
yeah, I mean I don’t think as a mum you’d want your child to be in any pain so if someone tells you take this and it’s not 
gonna hurt you’d do it wouldn’t you?
Y005a (White British mother, fully immunised children, individual interview)
5 What if the paracetamol actually doesn’t lower the fever then at what point do I say, you know, cos if I go to the doctors and 
say, oh, you know, he’s had the vaccinations but he’s got a fever, and they tend to say, oh yeah, it’s absolutely fine, it’s due 
to the vaccinations, but then at what point do I say, OK, well he has had the vaccinations but the fever’s carried on going 
up, paracetamol’s not working, given him Ibuprofen, what now?
L008c (Black British African mother, fully immunised children, group interview)
6 I think if it was me as well I would have issues about the appropriateness of just giving (name of daughter) paracetamol for 
the sake of giving her paracetamol when she’s not got a temperature. So I could understand, I think I would feel happier 
giving her a dose of paracetamol for, for a temperature rather than a dose of paracetamol just for the sake of having 
paracetamol. I don’t think I would probably give (name of daughter) the paracetamol, if she was asleep I wouldn’t wake her 
up.
L005a (White British mother, fully immunised children, individual interview)
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parents wanted even more visits with fewer injections at 
each. These preferences were predominantly to avoid 
fever (if that is associated with the MenB vaccine at 
this age) and distress to the baby on the day (quote 4, 
table 5). A small number of parents talked about prefer-
ring to avoid overloading their child’s immune system 
with multiple vaccines. These issues were more important 
for these parents than the potential inconvenience of 
multiple appointments.
A few parents suggested that they should be given a 
choice about the 12-month booster visit as they know what 
works best for their child. Similar numbers of parents 
disagreed, preferring to be offered the safest approach 
as well as acknowledging the difficulty of implementing 
a choice system.
Information needs
Information about MenB disease
Parents wanted to understand why MenB disease is 
something they need to vaccinate their child against. To 
achieve this, they wanted to know how to recognise it, 
what are the signs and symptoms (identified as the most 
important information; quote 1, table 6) and how many 
people catch it. They were also interested in who is most 
at risk, how it spreads and how it is different to other 
strains of meningococcal disease.
Information about MenB vaccine
Parents identified the most important information to be 
about the vaccine’s short-term and long-term side effects, 
likely occurrence and how to respond to them (quote 1, 
table 6). They also wanted information that compares the 
benefits versus the risks of the vaccine, facts on how it 
has been tested and if it has been used elsewhere. Other 
details of the vaccine that parents were interested in were: 
the reason it is needed in addition to MenC vaccine, why 
it does not protect against all meningococcal disease and 
how it is administered (number and timing of doses, injec-
tion/oral/nasal spray). They also wanted to understand 
why it causes fever, the likelihood of fever if administered 
alongside other vaccines and what would prevent their 
child having the injection on the day.
Information about fever and paracetamol
Parents identified the most important information 
about fever and paracetamol to be about how to admin-
ister paracetamol following MenB vaccination (dose, 
frequency, what happens if it does not work (quote 2, 
table 6). They also wanted to be informed of alternatives 
to giving paracetamol, and advised whether they should 
wake a sleeping baby to administer the paracetamol. 
Understanding what level and length of fever is normal, 
when should they be concerned and where should they 
go to seek help was also a priority.
Timing of information
Most parents preferred to have information about MenB 
vaccine and the associated fever before they attend the 
appointment (quote 3, table 6). Suggested methods of 
doing this were: sending the leaflet out with the invitation 
letter, giving it to the parent when they book the appoint-
ment at the GP practice or the practice nurse/health 
visitor providing it in routine appointments a few weeks 
before. A few parents said that while they would prefer 
to receive the MenB vaccine leaflet in advance, they 
would want the paracetamol leaflet at the appointment as 
that is the time they will focus on the specifics of timing 
and dosage (quote 4, table 6). Two parents talked about 
preferring to have information about all vaccinations 
before the baby is born as they had time and ‘headspace’ 
then to read it (quote 5, table 6).
DISCUSSION
This study explored parents’ knowledge of and attitudes 
to MenB disease and of MenB vaccine, and parents’ 
information needs to inform (a) the introduction of the 
MenB vaccine into the childhood schedule and (b) the 
information materials developed by PHE. To our knowl-
edge, this is the only current UK study providing detailed, 
Table 5 Illustrative quotes—acceptability of four vaccines at 12-month booster visit
1 I just put my trust in the fact that it's the best thing for her and I'm sure the healthcare professionals know what they are 
doing and so I don't think about it too much.
L004b (White British mother, fully immunised children, group interview)
2 I just, with having two really young children, the logistics of getting a doctor's appointment, getting there, and if, it sounds 
odd but if they're gonna be ill anyway, and as long as the fever's not more dangerous, I'm not too, I, I don't feel strongly.
L001a (White British mother, fully immunised children, group interview)
3 I know it’s not nice when they’re having it done, but it only lasts for a few minutes, and I think for the sake of having the 
whole build up of going back again for another set and will they get another fever again and will it happen again, I think 
sometimes it’s just… Best to get it all out of the way, let them have their five min’ cry and forget it. (laughter)
L003c (White British mother, fully immunised children, group interview)
4 I’ll prefer to split because her immune system, you know, can be built and have a chance; if you give too much, you never 
know what could happen. OK, it’s in one sense that’s like, you know, we have to come back a few times, but on the other 
hand it’s my baby, you know, health, so…
L003a (Polish mother, partially immunised children, group interview)
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up-to-date information for PHE and primary care health 
professionals to facilitate the successful implementation 
of MenB vaccine.
Our aim was to capture the views of parents across the 
two broad categories of parental factors that influence 
uptake of childhood vaccination (socioeconomic disad-
vantage, concern about safety or necessity of vaccines).13–18 
Although the proportion of parents in this study with a 
university degree (55%) was higher than the proportion 
reported nationally for a comparable age group (about 
40%),20 diversity was achieved in other factors which are 
associated with uptake of childhood vaccination, namely 
ethnicity, parental age and number of children. We 
recruited in settings outside the National Health Service 
(NHS) increasing the likelihood of speaking to parents 
with a range of views. We have no reason to believe that 
the parents in this study from Yorkshire and London are 
markedly different to other parents in the UK; either in 
terms of their social contexts which impact on their access 
to immunisation services or their acceptance of immuni-
sation. With the exception of one mother, the parents 
self-reported to be full or partial immunisers, reflecting 
the parents most likely to attend for MenB vaccination.
We investigated similarities and differences in views 
across parents of different education, ethnicity and 
number of children; and only identified a small number 
of differing views according to the number of children a 
parent had. As with all interview studies, there may have 
been some ‘social desirability’ in participants’ accounts 
and responses could have been influenced by others in 
the group interviews. These group interviews were usually 
with mothers attending the same mother and baby group, 
or groups of friends and couples. They were typically lively 
discussions and we observed many frank exchanges of 
opinion with conflicting views emerging on several issues. 
This is reassuring. Moreover, the parents interviewed all 
had very young children, they had recent experience of 
the immunisation process and of making immunisation 
decisions. However, at the time of the study the introduc-
tion of MenB vaccine had not yet been announced and so 
parents’ views about the vaccine, in particular, whether it 
would be acceptable were hypothetical.
Although most of the parents surveyed were not familiar 
with the term meningococcal disease, they recognised 
meningitis and septicaemia to be serious, life-threatening 
conditions. In their consideration of MenB, it was clear 
that for these parents, trusting the NHS and, by defini-
tion, healthcare professionals, is a key influence on their 
acceptance of vaccines. This is a finding that has been 
repeatedly reported elsewhere.21 22 This was evident in the 
view expressed by many parents that they will accept new 
vaccines or changes to the schedule because they trust the 
Table 6 Illustrative quotes—information needs
1 Well I like, obviously that, you know, this would make me, the statistics would make me think oh right, I need to get that 
done, the fear of the disease, you know, knowing what it is and what it can do would make, help me make the decision as 
well. And then, but then this one has all about the signs and symptoms and things like that, which, I mean you would want 
to know especially after the injection, more information about how to deal with the effects of the illness itself.
Y008a (White British mother, fully immunised children, individual interview)
2 Q. What's the most important issue for you to know about the paracetamol and fever? What's the key thing the leaflet 
needs to include?
How much.
Y007e (White British father, fully immunised children, group interview)
How often.
Y007b (White British mother, fully immunised children, group interview)
…like a big space in sort of like, cos it only says here, I mean a lot of people might skim over that or misread it, for the dose
Y007d (White British mother, fully immunised children, group interview)
Q. So the dose is the key thing you want guidance on?
Yeah.
Y007d
3 Q. When would you want to get this leaflet, when would it be most useful?
I guess maybe with the letter that you get to take, you know. Yeah, cos I wouldn’t want it to arrive for the vaccination and be 
like, right, here’s a leaflet do you want it now? I’d be like oh my gosh, I don’t know, but maybe with a letter when you’re due 
for your vaccination saying, you know, this is the new one, would you be happy to have it? At least then I can book then…
Y008a (White British mother, fully immunised children, individual interview)
4 I would want this on the day at the time as you would if you were going for anything to your doctors, so that you can use it 
as a, a refer to for whatever treatment you’ve then got to follow when you get home.
Y005a (White British mother, fully immunised children, individual interview)
5 Um (pause) probably before they have the baby, I think, because when you've just had a baby and you're all over the place 
and your life is completely turned upside down and then you have to take your sleep deprived self and the baby at eight 
weeks to have their first vaccination, I think, you know, even if people don't read it, when they go to antenatal classes or the 
midwife gives them it, I think you're more likely when you're pregnant to have the time to do it, especially when it's your first 
baby, when you're more focused on just that.
L001a (White British mother, fully immunised children, group interview)
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NHS to make evidence-based decisions and in particular, 
that vaccines have been appropriately tried and tested.
This also appeared to be the case for fever, if pre-warned 
that this is a likely consequence of MenB vaccine, most 
would not be deterred from accepting the vaccine. 
Advising parents of the likely adverse events following a 
vaccine is an important part of the immunisation process. 
Vaccine safety is a top priority for parents and if prepared 
for side effects with advice on their management, they are 
likely to be less concerned. This was borne out in one 
trial of the MenB vaccine, which included cohorts of 
parents who either knew or did not know which vaccines 
their child was receiving. Medical attention rates for fever 
were lower among parents who knew their child was 
receiving MenB vaccine, underlining the importance of 
advising parents about the possibility of fever following 
this vaccine.23
Based on parental reports of their experiences of the 
immunisation process, we identified elements where 
improvements are required. For example, some mothers 
reported feeling pressurised into accepting vaccines 
and first-time mothers in particular found the process 
stressful. Healthcare professionals may need reminding 
that the nature of their interactions is a key factor in 
influencing a parent’s attitudes to immunisation24; this 
includes not assuming that attendance for immunisation 
indicates parents have no questions or concerns. Making 
this assumption or lacking empathy about parents’ 
distress over the pain their child is experiencing may lead 
to future defaulting.25 This is particularly important with 
the introduction of MenB vaccine, when infants will be 
given three injections at their first immunisation visit at 
8 weeks of age.
In contrast, it has also been reported that healthcare 
professionals may overestimate parents’ concerns about 
their child receiving multiple injections.9 Although some 
parents in our study expressed concern about the pain, 
distress and possible impact on their child’s immune 
system of having an additional injection, most felt this 
was outweighed by the value of protection against such a 
serious infection. The introduction of MenB will have led 
to some initial queries or concerns from both healthcare 
professionals and parents about the need for an addi-
tional injection, but experience from the introduction of 
other vaccines suggests that it quickly becomes acceptable 
practice.9 Again, this underlines the importance of a posi-
tive recommendation from a confident, well informed 
healthcare professional in securing parental acceptance 
of vaccines.9
MenB vaccine is another significant milestone in the 
prevention of bacterial meningitis and septicaemia. Our 
findings mirror those from other studies conducted 
in other high-income countries in Europe26–28 and 
Australia,29 although there were considerable differences 
in the populations sampled in terms of age and sampling 
methods. Only one other study explicitly explored 
the hypothetical impact on vaccine acceptance of an 
increased risk of mild-to-moderate fever associated with 
the vaccine. That study reported that it reduced intent to 
immunise for only a small proportion.29 The recommen-
dation to give prophylactic paracetamol after the MenB 
doses at 2 and 4 months represents a change in advice 
with potential for confusion. Most parents in our study 
reported that despite some concerns, if advised to do so 
they would be likely to administer paracetamol. However, 
some may be reluctant and healthcare professionals need 
to be equipped to discuss this issue with parents. It will 
be important to monitor the side effects of MenB vaccine 
on a population level and whether increased rates of 
fever affect uptake of the vaccine or attendance rates in 
primary care and Accident and Emergency.
The successful implementation of the MenB vaccination 
programme requires: increased parental awareness of the 
infection, the safety and effectiveness of the vaccine, the 
likelihood of fever and its management if given concom-
itantly with other vaccines as well as the safety of giving 
multiple vaccines. Although we did not identify any new 
issues for parents in this study regarding vaccines, it was 
still important to explore their views and to consider their 
information needs. PHE developed written information 
for parents, which was informed by our findings.30–32 
Resources to support the introduction of the vaccine 
were also developed for healthcare professionals.33
In view of the successful implementation of other 
vaccines to prevent meningitis and septicaemia (Haemoph-
ilus influenzae type b, MenC, pneumococcal conjugate 
vaccine)34 and on the basis that parents’ perceptions of 
the severity of a disease is an important determinant of 
vaccine uptake,19 the prospects for the successful intro-
duction of MenB vaccine seem good. MenB vaccine was 
introduced into the routine vaccine schedule in the UK 
in September 2015 with three doses given at 2, 4 and 12 
months concomitantly with other vaccines.35 Preliminary 
vaccine coverage data suggest this has successfully been 
integrated into the national programme with uptakes of 
94.3% for one dose and 91.5% for two doses at 12 months 
of age.36 Our findings may be useful for other high-in-
come countries when considering the implementation 
of a MenB vaccine programme in highlighting poten-
tial issues that need to be addressed. However, in view of 
differences between population groups in terms of atti-
tudes to, and acceptability of, specific vaccines, it would 
be important to explore whether other issues may apply 
that could influence vaccine acceptance.
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